Epilepsy is a chronic and debilitating neurological disorder, known for the occurrence of spontaneous and recurrent seizures. Despite the availability of antiseizure drugs, 30% of people with epilepsy experience uncontrolled seizures and drug resistance, evidencing that new therapeutic options are required. The process of epileptogenesis involves the development and expansion of tissue capable of generating spontaneous recurrent seizures, during which numerous events take place, namely blood-brain barrier (BBB) dysfunction, and neuroinflammation. The consequent cerebrovascular dysfunction results in a lower seizure threshold, seizure recurrence, and chronic epilepsy. This suggests that improving cerebrovascular health may interrupt the pathological cycle responsible for disease development and progression. Krüppel-like factors (KLFs) are a family of zinc-finger transcription factors, encountered in brain endothelial cells, glial cells, and neurons. KLFs are known to regulate vascular function and changes in their expression are associated with neuroinflammation and human diseases, including epilepsy. Hence, KLFs have demonstrated various roles in cerebrovascular dysfunction and epileptogenesis. This review critically discusses the purpose of KLFs in epileptogenic mechanisms and BBB dysfunction, as well as the potential of their pharmacological modulation as therapeutic approach for epilepsy treatment.
Keyphrases
- blood brain barrier
- temporal lobe epilepsy
- cerebral ischemia
- endothelial cells
- oxidative stress
- healthcare
- transcription factor
- traumatic brain injury
- poor prognosis
- risk assessment
- induced apoptosis
- mental health
- cognitive impairment
- spinal cord
- multiple sclerosis
- lps induced
- human health
- spinal cord injury
- drug induced
- climate change
- resting state
- subarachnoid hemorrhage
- signaling pathway
- social media
- health promotion
- cell cycle arrest
- replacement therapy